Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care
May 27, 2021 Adding dapagliflozin to standard heart failure therapies provides “intermediate value” for American patients who have heart failure with reduced ejection fraction (HFrEF), a new cost-effectiveness analysis suggests—at odds with earlier analyses that suggested the cost per quality-adjusted life-year (QALY) would be below the accepted $50,000 cutoff. That’s because earlier studies, focused on settings outside the United States, considered both the “markedly lower” costs of the drug in countries like the United Kingdom, Germany, and Spain, as well as the lower overall he...